Nektar Therapeutics (NKTR) shares were up more than 9% in recent Friday trading after Oppenheimer upgraded the company's stock to outperform from market perform, with a price target of $6.
Trading volume was above 1.8 million shares against a daily average of roughly 2 million.
Price: 0.89, Change: +0.07, Percent Change: +9.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.